Evaluation of potential predictive diagnostic methods for specifity, distribution and relevance of immune checkpoint proteins (EPPIC)

Study identification

• EU PAS number:
  EUPAS37779
• Study ID:
  37780
• Official title and acronym:
  Evaluation of potential predictive diagnostic methods for specifity, distribution and relevance of immune checkpoint proteins (EPPIC)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  The aim of this study is the establishment of reliable and robust test methods for evaluation of immune checkpoint proteins in tumor tissues to predict efficiacy of targeted therapeutic strategies. We focus on cancers of the upper gastrointestinal tract obtained from surgical specimens without further or additional interventions.
• Study status:
  Ongoing

Research institutions and networks

Institutions

University Hospital of Cologne

Institute of Pathology

Study timelines

Date when funding contract was signed

Planned:27/10/2020

Actual:27/10/2020

Study start date

Planned:27/10/2020

Actual:27/10/2020

Date of final study report

Planned:27/10/2025

Sources of funding

Other

More details on funding

Institute of Pathology, University Hospital of Cologne

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable